AAAAAA
Results:
1-22
|
Results: 22
Authors:
McLeod, D
Zinner, N
Tomera, K
Gleason, D
Fotheringham, N
Campion, M
Garnick, MB
Citation: D. Mcleod et al., A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer, UROLOGY, 58(5), 2001, pp. 756-761
Authors:
Tomera, K
Gleason, D
Gittelman, M
Moseley, W
Zinner, N
Murdoch, M
Menon, M
Campion, M
Garnick, MB
Citation: K. Tomera et al., The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer, J UROL, 165(5), 2001, pp. 1585-1589
Authors:
Joyal, JL
Israel, DI
Garnick, MB
Citation: Jl. Joyal et al., Comments on an in vitro model of hormonally refractory prostate cancer, CANCER J, 6(4), 2000, pp. 213-214
Authors:
Garnick, MB
Fair, WR
Bostwick, D
Debruyne, F
Fourcroy, J
Grignon, D
Porterfield, H
Sufrin, G
Thrasher, B
Hart, C
Citation: Mb. Garnick et al., Fifth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer - Overview consensus statement, MOL UROL, 4(3), 2000, pp. 89-92
Authors:
Garnick, MB
Campion, M
Citation: Mb. Garnick et M. Campion, Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: Differential effects on follicle-stimulating hormone, MOL UROL, 4(3), 2000, pp. 275-277
Authors:
Garnick, MB
Fair, WR
Goldenberg, SL
Gleave, M
Grignon, D
Fourcroy, J
Sufrin, G
Porterfield, H
Hart, C
Citation: Mb. Garnick et al., Fourth International Conference on Neoadjuvant Hormonal Therapy of Prostate Cancer - March 12-13, 1999 - Boston, Massachusetts - Overview consensus statement, MOL UROL, 3(3), 1999, pp. 171-174
Authors:
Garnick, MB
Citation: Mb. Garnick, Hormonal therapy in the management of prostate cancer: An historical overview, MOL UROL, 3(3), 1999, pp. 175-182
Authors:
Grignon, DJ
Bostwick, DG
Civantos, F
Garnick, MB
Gaudin, P
Srigley, JR
Citation: Dj. Grignon et al., Pathologic handling and reporting of prostate tissue specimens in patientsreceiving neoadjuvant hormonal therapy: Report of the Pathology Committee, MOL UROL, 3(3), 1999, pp. 193-197
Authors:
Shames, D
Garnick, MB
Citation: D. Shames et Mb. Garnick, Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease - Editorial comments, UROLOGY, 54(2), 1999, pp. 323-324
Authors:
Garnick, MB
Citation: Mb. Garnick, Disclosure statements regarding hormonal treatment of prostate cancer, N ENG J MED, 340(21), 1999, pp. 1689-1689
Authors:
Garnick, MB
Citation: Mb. Garnick, Hormonal treatment of prostate cancer, N ENG J MED, 340(10), 1999, pp. 812-812
Authors:
Garnick, MB
Fair, WR
Goldenberg, SL
Gleave, M
Fourcroy, J
Grignon, D
Srougi, M
Porterfield, H
Hart, C
Citation: Mb. Garnick et al., Third International Conference on Neoadjuvant Hormonal Therapy of ProstateCancer: Overview consensus statement, MOL UROL, 2(3), 1998, pp. 87-89
Authors:
Garnick, MB
Civantos, F
Bostwick, D
Schulman, CC
Citation: Mb. Garnick et al., Histologic basis and optimal duration for neoadjuvant androgen deprivationtherapy - Discussion, MOL UROL, 2(3), 1998, pp. 101-101
Authors:
Garnick, MB
Stock, RG
Roach, M
Citation: Mb. Garnick et al., Neoadjuvant androgen suppression and permanent radioactive seed implantation in the treatment of stage T-1-T-2 prostate cancer - Discussion, MOL UROL, 2(3), 1998, pp. 127-127
Authors:
McLeod, D
Civantos, F
Schulman, CC
Roach, M
Grignon, D
Fair, WR
Bostwick, D
Goldenberg, L
Garnick, MB
Trachtenberg, J
Citation: D. Mcleod et al., Radical prostatectomy nu radical prostatectomy preceded by combined androgen blockade in clinical stage B-2 (T2bNxM0) prostate cancer: An update - Discussion, MOL UROL, 2(3), 1998, pp. 163-164
Authors:
Rabbani, F
Garnick, MB
Goldenberg, SL
Gleave, M
Fourcroy, J
Citation: F. Rabbani et al., Randomized trial of neoadjuvant androgen ablation prior to radical prostatectomy: 24-month post-treatment PSA results - Discussion, MOL UROL, 2(3), 1998, pp. 169-169
Authors:
Goldenberg, L
Schulman, CC
Fair, WR
Gleave, M
Garnick, MB
Bostwick, D
Grignon, D
Rabbani, F
Citation: L. Goldenberg et al., Results of a European randomized study comparing radical prostatectomy andradical prostatectomy plus neoadjuvant hormonal combination therapy in stage T2-3NoMo prostatic carcinoma - Open discussion, MOL UROL, 2(3), 1998, pp. 187-187
Authors:
Garnick, MB
Gleave, M
Heston, WDW
Pienta, KJ
Citation: Mb. Garnick et al., Neither PSMA RT-PCR nor MTHFR genotype predicts PSA failure after prostatectomy - Open discussion, MOL UROL, 2(3), 1998, pp. 227-227
Authors:
Garnick, MB
Snow, PB
Trachtenberg, J
Howell, S
Bostwick, D
Citation: Mb. Garnick et al., Artificial neural networks applied to the diagnosis and prognosis of prostate cancer - Open discussion, MOL UROL, 2(3), 1998, pp. 245-245
Authors:
Fair, WR
Pienta, KJ
Trachtenberg, J
Gleave, M
Bostwick, D
Garzotto, M
Garnick, MB
Citation: Wr. Fair et al., Mechanisms of androgen resistance in prostate cancer - Open discussion, MOL UROL, 2(3), 1998, pp. 263-263
Authors:
Molineaux, CJ
Sluss, PM
Bree, MP
Gefter, ML
Sullivan, LM
Garnick, MB
Citation: Cj. Molineaux et al., Suppression of plasma gonadotropins by abarelix: A potent new LHRH antagonist, MOL UROL, 2(3), 1998, pp. 265-268
Authors:
Garzotto, M
Garnick, MB
Fair, WR
Citation: M. Garzotto et al., Suppression of plasma gonadotropins by abarelix: A potent new LHRH antagonist - Open discussion, MOL UROL, 2(3), 1998, pp. 269-269
Risultati:
1-22
|